

PRESS RELEASE

14 September 2023

Sponsorship of the WICH 2023 congress and oral presentations.

Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience in cerebral haemorrhage.

The World Intracranial Hemorrhage Conference (WICH) meets every two years and brings together neurologists, neurosurgeons, researchers and clinicians from all fields, healthcare providers, students and community members from around the world to provide a unique opportunity to exchange ideas and share research and clinical innovations in the field of intracranial haemorrhage. The WICH 2023 conference will bring together world-renowned speakers to share, discuss, debate and dissect significant new developments and scientific advances in the field of intracerebral, subarachnoid and subdural haemorrhage.

Op2Lysis will be an official sponsor of this 8th edition, which will take place on 8 and 9 October 2023 in Toronto (Canada). The company will also have the opportunity to take an active part in the discussions through two presentations given by Christophe GAUDIN to share Op2Lysis orphan designation granting experience at the combined HEADS/CoHESIVE meeting which will take place alongside the WICH conference on 7 October 2023, and by Jérôme PARCQ, during the scientific debates on 8 October 2023 to present the latest results on O2L-001 in the treatment of cerebral haemorrhage.

"Our active participation in a conference such as WICH demonstrates our commitment to moving the frontiers in the treatment of cerebral haemorrhage and the quality of our work, as evidenced by the two oral presentations we will be giving during the three-day conference including HEADS and WICH. We are delighted to be sponsor of this event where experts and decision-makers in the cerebral haemorrhage community are brought together. This opportunity gives us additional visibility with investigators and industry and allows us to actively prepare our future clinical trials." - Christophe Gaudin, co-founder of Op2Lysis.

Boulogne-Billancourt, 14 September 2023

For further information, please contact :


Christophe Gaudin, CEO

- christophe.gaudin@op2lysis.com
- ① +33 607 979 008
- www.op2lysis.com

Jérôme Parcq, CSO

- jerome.parcq@op2lysis.com
- ① +33 615 270 969
- <https://www.linkedin.com/company/op2lysis>

About [Op2Lysis - www.op2lysis.com](http://www.op2lysis.com)

 Op2Lysis is a biotechnology company specialising in the development of novel therapies to address unmet needs in cerebrovascular diseases. With its first drug, O2L-001, Op2Lysis is dedicated to developing the first medical treatment for deep haemorrhagic stroke, the most debilitating form of stroke. Op2Lysis aims to become a leader in the development of treatments for all forms of cerebral haemorrhage. Op2Lysis benefits from the dynamic ecosystems of the regions in which the company is based, Caen and Liège.

Op2Lysis SAS: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France
GIP Cyceron, Boulevard Henri Becquerel, 14000 Caen, France

Op2Lysis Development SA : Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

About O2L-001

O2L-001 is a locally administered treatment designed to liquefy the intracerebral haematoma that has formed following a cerebral haemorrhage, in order to evacuate it and reduce its deleterious mass effect. O2L-001 has been specifically designed for large, deep haematomas. Its development is based on documented clinical proof of concept (MISTIE programme), including the demonstration of a robust association between reduction in blood volume and reduction in disability. The competitive advantages of O2L-001 observed in the best translational models indicate the potential for major efficacy and increased safety in this therapeutic indication. O2L-001 should radically change practice in this therapeutic indication.

About HEADS/CoHESIVE

The HEmorrhagic stroke Academia inDuStry (HEADS) roundtable and the Canadian Hemorrhagic Stroke Trials Initiative (CoHESIVE) collaboration is designed to be a collaborative discussion between select world-renowned leaders in the field of hemorrhagic stroke from academia, device & pharmaceutical companies, and governmental regulatory and research agencies to define unmet needs in the field and to address impediments to maximize opportunities for successfully, efficiently, and rapidly mounting and completing pivotal hemorrhagic stroke studies encompassing the entire R&D process. Attendance at this meeting is by invitation only. The summary and recommendations from this important meeting will be published in the STROKE journal.